Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jun;38(6):1356–1362. doi: 10.1128/aac.38.6.1356

Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve.

P G Davey 1, M Charter 1, S Kelly 1, T R Varma 1, I Jacobson 1, A Freeman 1, E Precious 1, J Lambert 1
PMCID: PMC188210  PMID: 8092837

Abstract

Patients undergoing elective surgery for removal of brain tumors, aneurysms, or other vascular malformations were administered a single oral dose of sparfloxacin (400 mg; 16 patients) or ciprofloxacin (750 mg; 5 patients) either 3 to 5 h or 22 to 26 h before surgery. Serum samples were taken from all patients at 0, 1, 3 to 5, 7 to 9, and 22 to 26 h after dosing; an additional serum sample was obtained at 48 h from patients who received sparfloxacin. A single sample of brain tissue was taken from all patients; a sample of cerebrospinal fluid (CSF) uncontaminated with blood was obtained from five patients. Serum and brain tissue samples were assayed by high-pressure liquid chromatography. Drug concentrations in brain tissue exceeded those in CSF by 1.8- to 19.4-fold. Kinetic modeling suggested that peak sparfloxacin concentrations in brain tissue may have occurred later than 3 to 5 h and that actual peak concentrations may therefore have been higher (up to 10 micrograms/g of tissue). The activities of ciprofloxacin and sparfloxacin as antagonists of the gamma-aminobutyric acid antagonist (GABAA) receptor were measured with the rat vagus nerve preparation. The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml). In contrast, the IC50 of sparfloxacin alone or in the presence of BPAA was > 300 microM (> 100 micrograms/ml). We conclude that the concentrations of ciprofloxacin and sparfloxacin in brain tissue may exceed serum drug concentrations and cannot be predicted from the concentrations in CSF. Sparfloxacin does not have any activity as a GABA antagonist, either alone or in the presence of BPAA, at the concentrations which are likely to be reached in human brain tissue.

Full text

PDF
1356

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Fuchs P. C. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991 May;35(5):955–960. doi: 10.1128/aac.35.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chiccarelli F. S., Eisner H. J., Van Lear G. E. Metabolic and pharmacokinetic studies with fenbufen in man. Arzneimittelforschung. 1980;30(4A):728–735. [PubMed] [Google Scholar]
  3. Davey P. G., McDonald T., Lindsay G. Post-marketing surveillance of quinolones 1988-1990. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):384–389. doi: 10.1007/BF01967015. [DOI] [PubMed] [Google Scholar]
  4. Donald F. E. Treatment of brain abscess. J Antimicrob Chemother. 1990 Mar;25(3):310–312. doi: 10.1093/jac/25.3.310. [DOI] [PubMed] [Google Scholar]
  5. Fleming L. W., Moreland T. A., Scott A. C., Stewart W. K., White L. O. Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother. 1987 Apr;19(4):493–503. doi: 10.1093/jac/19.4.493. [DOI] [PubMed] [Google Scholar]
  6. Halliwell R. F., Davey P. G., Lambert J. J. Antagonism of GABAA receptors by 4-quinolones. J Antimicrob Chemother. 1993 Apr;31(4):457–462. doi: 10.1093/jac/31.4.457. [DOI] [PubMed] [Google Scholar]
  7. Halliwell R. F., Davey P. G., Lambert J. J. The effects of quinolones and NSAIDs upon GABA-evoked currents recorded from rat dorsal root ganglion neurones. J Antimicrob Chemother. 1991 Feb;27(2):209–218. doi: 10.1093/jac/27.2.209. [DOI] [PubMed] [Google Scholar]
  8. Lucht F., Dorche G., Aubert G., Boissier C., Bertrand A. M., Brunon J. The penetration of ceftriaxone into human brain tissue. J Antimicrob Chemother. 1990 Jul;26(1):81–86. doi: 10.1093/jac/26.1.81. [DOI] [PubMed] [Google Scholar]
  9. McAinsh J., Cruickshank J. M. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990;46(2):163–197. doi: 10.1016/0163-7258(90)90092-g. [DOI] [PubMed] [Google Scholar]
  10. Richards J., Sisson P. R., Hickman J. E., Ingham H. R., Selkon J. B. Microbiology, chemotherapy and mortality of brain abscess in Newcastle-upon-Tyne between 1979 and 1988. Scand J Infect Dis. 1990;22(5):511–518. doi: 10.3109/00365549009027089. [DOI] [PubMed] [Google Scholar]
  11. Sjölin J., Eriksson N., Arneborn P., Cars O. Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans. Antimicrob Agents Chemother. 1991 Dec;35(12):2606–2610. doi: 10.1128/aac.35.12.2606. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES